Information Provided By:
Fly News Breaks for June 5, 2019
Jun 5, 2019 | 07:51 EDT
Cowen analyst Charles Ryhee believes the organic growth concerns and NCQA reaccreditation for Teladoc are overblown. The analyst sees a favorable macro environment for telehealth and a potential upside to Q2 from higher than expected visit growth. He also sees future growth benefiting from increasing access to telehealth in Medicare and Medicaid, and improving reimbursement parity. Ryhee reiterated his Outperform rating and $82 price target on Teladoc shares.
News For TDOC From the Last 2 Days
There are no results for your query TDOC